Built so your team can act on cancer sooner.
Simsen Diagnostics exists for one reason: to put ultra-sensitive ctDNA within reach of the teams treating and studying cancer, in Europe, on your terms. This page is the why behind that, and what it means for the work you do.
Give every oncology team the signal they need, early enough to use it.
We make ultra-sensitive sequencing easy, so healthcare and pharmaceutical leaders can monitor cancer with precision and make data-driven decisions for better patient outcomes.
A future where cancer is a curable disease.
By advancing personalised ctDNA monitoring, we aim to give clinicians and researchers the tools to detect, monitor and treat cancer with unmatched precision, bringing the field closer to a world free from its burden.
The signal was always there. The access was not.
Circulating tumour DNA tells you whether disease is responding, residual or returning, often months before imaging can. The problem was never the biology. It was getting that sensitivity into the hands of the teams who need it, without sending samples across the world or rebuilding your lab.
Simsen was founded in Gothenburg in 2020 by the inventors of SiMSen-Seq, Professor Anders Ståhlberg and Professor Tony Godfrey, together with Professor Mikael Kubista and GU Ventures. The method had already been published in Nature Protocols. The company exists to turn that science into a service teams across Europe can actually use.
SiMSen-Seq drives error-corrected sequencing down to parts-per-million sensitivity. For your patients and your studies, that means catching residual disease and early relapse when the window to act is still open, not after.
We deliver it your way. Send us samples and receive clear, interpreted reports from our lab, or run our personalised panels in your own laboratory with LabSuite. Either route, you keep control and you keep the relationship with a European partner working in your time zone.
Today we work with research hospitals, private cancer clinics and pharmaceutical companies, with a clear growth plan and further European expansion underway. The mission has not changed since day one: earlier, more certain answers for the people you treat and study.
Simsen at a glance
Five things we hold ourselves to.
The same five promises run through every page on this site, retold in your language on each Solutions page. Here is the short version.
Sensitivity
Parts-per-million detection, so you see disease while there is still time to act.
Flexibility
Full service or run it in-house with LabSuite. Your samples, your choice.
Clinical insight
Clear, interpreted reporting, not just raw data dumped on your desk.
Transparency
Partnership
A European team in your time zone, open to co-publication and long-term work.
From a published method to a working partner.
A short history of the milestones behind the service you would be working with.
-
2017
SiMSen-Seq published
The SiMSen-Seq method for ultra-sensitive, error-corrected sequencing is published in Nature Protocols.
-
2020
Simsen is founded
Inventors Prof. Anders Ståhlberg and Prof. Tony Godfrey incorporate the company with Prof. Mikael Kubista and GU Ventures to commercialise the method.
-
2021
Business begins
A 50 MSEK Vinnova grant is awarded, the first employee is hired, further patents are filed and a lab is established at Sahlgrenska Science Park.
-
2022
First customers
Research hospitals, international diagnostics companies and pharmaceutical companies sign on.
-
2023
Move to BioVentureHub
Office and lab move to AstraZeneca's BioVentureHub in Mölndal, on the edge of Gothenburg, Sweden. -
2024
Growth
More customers sign on, including the first private cancer clinic. A comprehensive QMS and GDPR framework is built, and a growth plan with international expansion begins.
-
2026
Where we are now
Cancer centres across the Nordics, the UK and Southern Europe are choosing Simsen for ctDNA analysis, from full-service monitoring to piloting testing in their own labs. As demand grows, we are preparing for ISO 15189 accreditation as well as ISO 9001 and 14001 certifications, and building the capacity to give every customer the same fast, reliable turnaround they rely on us for today.
Want to know if this fits your samples?
A real human, in CET/CEST time zone, who has run samples like yours. Tell us about your trial, your patients, or your lab.